
Sign up to save your podcasts
Or


Theresa Hoffmann, CEO and Co-founder of Nanoplume, discusses bio-based aerogel insulation, deep tech commercialisation, and the realities of early-stage founding on Episode 21 of Scaling Green Tech, a podcast by Adopter.
Hoffmann explains how 80% of the insulation market remains dependent on petrochemical materials, despite the thermal insulation industry growing toward a $100 billion market by 2030. Nanoplume's answer is a bio-based nano-porous material that is three times as insulating, 60% lighter and thinner, and 100% biocompatible - and around 75% cheaper than silica aerogels and other super-insulating materials. Rather than targeting the built environment first, Hoffmann describes a deliberate beachhead strategy in pharmaceutical cold chain logistics, chosen for clearer economics and lower mechanical requirements, with a roadmap toward truck insulation, warehousing, and eventually buildings. The episode also covers co-founder dynamics, founder identity, and how to validate market assumptions through early customer case studies.
This episode is relevant for deep tech founders at pre-seed and seed stage, materials science entrepreneurs, cold chain and pharmaceutical logistics investors, built environment innovators, and anyone navigating co-founder relationships, accelerator programmes, or early-stage commercialisation strategy.
Find out more about Adopter here: https://www.adopter.net/
Explore Nanoplume here: https://www.nanoplume.com/
Connect with Theresa on LinkedIn: https://www.linkedin.com/in/theresa-hoffmann/
By Matt Jaworski and Katherine KeddieTheresa Hoffmann, CEO and Co-founder of Nanoplume, discusses bio-based aerogel insulation, deep tech commercialisation, and the realities of early-stage founding on Episode 21 of Scaling Green Tech, a podcast by Adopter.
Hoffmann explains how 80% of the insulation market remains dependent on petrochemical materials, despite the thermal insulation industry growing toward a $100 billion market by 2030. Nanoplume's answer is a bio-based nano-porous material that is three times as insulating, 60% lighter and thinner, and 100% biocompatible - and around 75% cheaper than silica aerogels and other super-insulating materials. Rather than targeting the built environment first, Hoffmann describes a deliberate beachhead strategy in pharmaceutical cold chain logistics, chosen for clearer economics and lower mechanical requirements, with a roadmap toward truck insulation, warehousing, and eventually buildings. The episode also covers co-founder dynamics, founder identity, and how to validate market assumptions through early customer case studies.
This episode is relevant for deep tech founders at pre-seed and seed stage, materials science entrepreneurs, cold chain and pharmaceutical logistics investors, built environment innovators, and anyone navigating co-founder relationships, accelerator programmes, or early-stage commercialisation strategy.
Find out more about Adopter here: https://www.adopter.net/
Explore Nanoplume here: https://www.nanoplume.com/
Connect with Theresa on LinkedIn: https://www.linkedin.com/in/theresa-hoffmann/